JETEMA Co.,Ltd.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureJETEMA Co.,Ltd. was founded in 2009 and listed on KOSDAQ in 2019 as a medical device company. It develops and manufactures hyaluronic acid dermal fillers, botulinum toxin-based biopharmaceuticals for facial aesthetics, and lifting threads for tissue suturing and facial fixation; its botulinum toxin product Jetema The Toxin Inj. 100U, indicated for glabellar line improvement, received marketing approval in December 2024 and launched domestically in March 2025. The company signed license-out agreements worth roughly KRW 600 billion combined with partners in Brazil (2020) and China (2022), a five-year toxin export contract worth about KRW 40 billion with a Thai partner in H1 2024, and established its US subsidiary Jetema USA Inc.; consolidated 2025 revenue was KRW 76.9 billion (up 12.2% year-on-year) with operating profit of KRW 3.8 billion (down 7.1% year-on-year).
Products & technology
- Jetema The Toxin Inj. 100UGlabellar line improvement
- Hyaluronic acid dermal fillerFacial aesthetics (tissue-repair biomaterial)
- Lifting threadTissue suturing and facial fixation
Regulatory approvals
data.go.kr3 Korean MFDS drug approvals · 2020–2024 / 75 Korean MFDS device approvals · 1999–2025
- MFDSGraft/prosthesis2025-10-24Product approval · Class 4제허 25-717 호
- MFDSGraft/prosthesis2025-10-24Product approval · Class 4제허 25-716 호
- MFDSPolydioxanone suture2025-06-10Product approval · Class 4제허 25-379 호
- MFDS drugJETEMA THE TOXIN Inj. 100U(Clostridium Botulinum Toxin Type A)2024-12-05Drug · Prescription · Approval202402879
- MFDSGraft/prosthesis, biomaterial2024-11-19Product approval · Class 4제허 24-813 호
- MFDSPolydioxanone suture2024-09-04Product approval · Class 4제허 24-607 호
- MFDSPolydioxanone suture2024-07-15Product approval · Class 4제허 24-482 호
- MFDSGraft/prosthesis2024-05-22Product approval · Class 4제허 24-347 호
- MFDSThread for facial tissue fixation, absorbable or non-absorbable2023-05-31Product approval · Class 4제허 23-627 호
- MFDSThread for facial tissue fixation, absorbable or non-absorbable2023-05-31Product approval · Class 4제허 23-625 호
- MFDSPolydioxanone suture2023-05-25Product approval · Class 4제허 23-612 호
- MFDSPolydioxanone suture2023-05-25Product approval · Class 4제허 23-611 호
Show 66 more
- MFDSGraft/prosthesis, biomaterial2023-03-02Product approval · Class 4제허 23-180 호
- MFDSGraft/prosthesis, biomaterial2023-01-30Product approval · Class 4제허 23-66 호
- MFDSGraft/prosthesis, biomaterial2023-01-30Product approval · Class 4제허 23-65 호
- MFDSGraft/prosthesis, biomaterial2022-03-14Product approval · Class 4제허 22-174 호
- MFDS drugJETEMA THE TOXIN Inj. 200U (Clostridium Botulinum toxin type A)2021-10-29Drug · Prescription · Approval202107200
- MFDSGraft/prosthesis, biomaterial2021-03-31Product approval · Class 4제허 21-235 호
- MFDSGraft/prosthesis, biomaterial2021-03-31Product approval · Class 4제허 21-234 호
- MFDSGraft/prosthesis2020-06-26Product approval · Class 4제허 20-517 호
- MFDS drugJETEMA THE TOXIN Inj. 100U (Clostridium Botulinum toxin type A)(for export)2020-06-04Drug · Prescription · Approval202004236
- MFDSGraft/prosthesis, biomaterial2020-02-03Product approval · Class 4제허 20-72 호
- MFDSPolydioxanone suture2019-10-02Product approval · Class 4제허 19-628 호
- MFDSGraft/prosthesis, biomaterial2019-07-09Product approval · Class 4제허 19-445 호
- MFDSGraft/prosthesis, biomaterial2019-07-09Product approval · Class 4제허 19-444 호
- MFDSGraft/prosthesis, biomaterial2019-02-21Product approval · Class 4수허 19-49 호
- MFDSGraft/prosthesis, biomaterial2019-02-21Product approval · Class 4수허 19-48 호
- MFDSPolydioxanone suture2018-12-04Product approval · Class 4제허 18-771 호
- MFDSThread for facial tissue fixation, absorbable or non-absorbable2018-04-18Product approval · Class 4제허 18-269 호
- MFDSThread for facial tissue fixation, absorbable or non-absorbable2018-04-18Product approval · Class 4제허 18-268 호
- MFDSThread for facial tissue fixation, absorbable or non-absorbable2018-03-05Product approval · Class 4제허 18-148 호
- MFDSThread for facial tissue fixation, absorbable or non-absorbable2018-03-05Product approval · Class 4제허 18-147 호
- MFDSSuture, absorbable2018-02-13Product approval · Class 4제허 18-89 호
- MFDSPolydioxanone suture2018-02-13Product approval · Class 4제허 18-86 호
- MFDSGraft/prosthesis, biomaterial2017-09-29Product approval · Class 4제허 17-766 호
- MFDSGraft/prosthesis, biomaterial2017-09-29Product approval · Class 4제허 17-765 호
- MFDSGraft/prosthesis, biomaterial2017-08-02Product approval · Class 4제허 17-594 호
- MFDSGraft/prosthesis, biomaterial2017-03-21Product approval · Class 4제허 17-203 호
- MFDSNeedle, aspiration/injection, reusableRevoked2015-06-18Product approval · Class 1서울 제신 15-225 호
- MFDSIndirect infusion deviceRevoked2015-06-18Product approval · Class 1서울 제신 15-224 호
- MFDSIndirect infusion deviceRevoked2015-03-17Product approval · Class 1서울 제신 15-99 호
- MFDSIndirect infusion deviceRevoked2015-03-17Product approval · Class 1서울 제신 15-98 호
- MFDSGraft/prosthesis, biomaterial2015-03-17Product approval · Class 4제허 15-365 호
- MFDSPharmacy compounding system, manually-operatedRevoked2015-03-11Product approval · Class 2제인 15-342 호
- MFDSDressing, adhesion barrierRevoked2014-12-19Product approval · Class 3제허 14-3195 호
- MFDSGraft/prosthesis, biomaterialRevoked2014-11-18Product approval · Class 4제허 14-2301 호
- MFDSGraft/prosthesis, biomaterial2014-10-01Product approval · Class 4제허 14-1768 호
- MFDSGraft/prosthesis, biomaterial2014-08-27Product approval · Class 4수허 14-2569 호
- MFDSIndirect infusion deviceRevoked2013-07-19Product approval · Class 1서울 제신 13-205 호
- MFDSIndirect infusion deviceRevoked2013-07-19Product approval · Class 1서울 제신 13-204 호
- MFDSIndirect infusion deviceRevoked2012-12-06Product approval · Class 1서울 제신 12-288 호
- MFDSLaser surgical unit, othersRevoked2012-10-08Product approval · Class 3수허 12-1423 호
- MFDSIndirect infusion deviceRevoked2011-09-15Product approval · Class 1서울 제신 11-189 호
- MFDSIndirect infusion deviceRevoked2011-04-08Product approval · Class 1서울 제신 11-56 호
- MFDSOximeter catheter, fibreopticRevoked2010-11-05Product approval · Class 2수허 10-1173 호
- MFDSIndirect infusion deviceRevoked2010-10-26Product approval · Class 1서울 제신 10-228 호
- MFDSLaser surgical unit, othersRevoked2010-06-29Product approval · Class 3수허 10-664 호
- MFDSLaser surgical unit, diodeRevoked2009-11-18Product approval · Class 3수허 09-1187 호
- MFDSLaser surgical unit, othersRevoked2009-11-12Product approval · Class 3제허 09-939 호
- MFDS광선조사기Revoked2009-03-27Product approval · Class 3제허 09-205 호
- MFDS레이저수술기Revoked2008-09-26Product approval · Class 3수허 08-927 호
- MFDS의약품주입용기구Revoked2008-03-21Product approval · Class 1제신 08-58 호
- MFDS레이저수술기Revoked2008-03-11Product approval · Class 3제허 08-139 호
- MFDSLaser surgical unit, othersRevoked2007-11-13Product approval · Class 3수허 07-980 호
- MFDS레이저수술기Revoked2007-05-18Product approval · Class 3제허 07-274 호
- MFDS고주파자극기Revoked2006-11-06Product approval · Class 3제허 06-826 호
- MFDS레이저수술기Revoked2006-04-28Product approval · Class 3수허 06-440 호
- MFDS광선조사기Revoked2006-01-17Product approval · Class 3제허 06-47 호
- MFDS레이저수술기Revoked2005-09-08Product approval · Class 3제허 05-731 호
- MFDS광선조사기Revoked2004-05-31Product approval · Class 3제허 04-547 호
- MFDS의약품주입용기구Revoked2004-04-16Product approval · Class 2제허 04-378 호
- MFDS레이저수술기Revoked2004-04-09Product approval · Class 3수허 04-479 호
- MFDS의약품주입용기구Revoked2004-02-25Product approval · Class 2제허 04-187 호
- MFDS레이저수술기Revoked2002-07-26Product approval · Class 2수허 02-844 호
- MFDS의료용석고절단기Revoked2001-12-12Product approval · Class 2제허 01-727 호
- MFDS의약품주입용기구Revoked2000-02-28Product approval · Class 2제허 00-75 호
- MFDS의약품주입용기구Revoked2000-02-28Product approval · Class 2제허 00-76 호
- MFDS의약품주입용기구Revoked1999-12-27Product approval · Class 2제허 99-378 호
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2020–2023 (Phase 1 2 · Phase 3 1)
- Phase 1제테마더톡신주 100단위(JTM201)2023-05-08
2 trial sites
- Phase 3제테마더톡신주 100단위(JTM201)2022-04-01
3 trial sites
- Phase 1제테마더톡신주 100단위(JTM201)2020-08-03
1 trial site
R&D and key agreements
Source: DART corporate disclosure보툴리눔 톡신 Type E · 안면미용 및 치료용 다양한 적응증(상처치유, 치핵절제, 치과임플란트, 관절치환술, 여드름, 과민성대장증후군, 근골격계 통증 등) · 적응증 및 차세대 제형 개발 단계 · Effect onset within 24 hours and duration of 2-4 weeks; being developed as a non-narcotic analgesic alternative with potential for expansion into multiple indications
보툴리눔 톡신(국내) · 상지 근육경직 치료 · 임상 1상 완료 · Completed Phase 1; preparing entry into the therapeutic market
보툴리눔 톡신(중국) · 미간 주름 개선 · 임상 1상 종료, 임상 3상 진행중
보툴리눔 톡신(미국) · 미간 주름 개선 · 임상 2상 완료(2025년 12월)
히알루론산 필러 안면볼륨 · 안면볼륨 개선 · 2024년 5월 임상시험계획 승인, 임상시험 진행중
히알루론산 필러 팔자주름 · 팔자주름 개선 · 2025년 7월 임상시험계획 승인, 임상시험 진행중
히알루론산 필러 미세주름 · 미세주름 개선 · 임상시험계획 단계
Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
Founded in 2019 and KOSDAQ-listed the same year, WON TECH makes aesthetic laser, RF, and HIFU devices including Oligio and Picocare.
Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.
Founded and KOSPI-listed in 2025, Samyang Biopharm develops medical devices, pharmaceuticals, and new drug candidates.
KOSDAQ-listed aesthetic medical device company producing PICO, DUAL HI, and other anti-aging and body-contouring devices.
KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition